BioPharmSignal logoBioPharmSignal

Biotech News

MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy

MiNK Therapeutics, Inc. (INKT)MiNK Therapeutics, Inc.Earnings

Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

Related news

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

INKTMiNK Therapeutics, Inc.2026-09-30 11:57 EST

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

View all latest news

MiNK Therapeutics, Inc.

Allogeneic iNKT Cell Therapy Company MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines. Its platform is designed to connect innate and adaptive immunity across cancer, autoimmune disease, and states of severe immune dysfunction. AgenT-797 Lead Asset AgenT-797 is an...

Recent company news

INKTMiNK Therapeutics, Inc.2026-11-02 21:35 EST

MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy

INKTMiNK Therapeutics, Inc.2026-10-02 13:00 EST

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

INKTMiNK Therapeutics, Inc.2026-09-30 11:57 EST

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

INKTMiNK Therapeutics, Inc.2026-08-13 11:30 EST

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

INKTMiNK Therapeutics, Inc.2026-08-06 16:00 EST

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

Stock data

Close
10.05 USD
Market cap
59.58M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States